@article{b64b933fde194d2786e0d6611158c666,
title = "The Alzheimer's Disease Neuroimaging Initiative 2 Biomarker Core: A review of progress and plans",
abstract = "Introduction We describe Alzheimer's Disease Neuroimaging Initiative (ADNI) Biomarker Core progress including: the Biobank; cerebrospinal fluid (CSF) amyloid beta (Aβ1-42), t-tau, and p-tau181 analytical performance, definition of Alzheimer's disease (AD) profile for plaque, and tangle burden detection and increased risk for progression to AD; AD disease heterogeneity; progress in standardization; and new studies using ADNI biofluids. Methods Review publications authored or coauthored by ADNI Biomarker core faculty and selected non-ADNI studies to deepen the understanding and interpretation of CSF Aβ1-42, t-tau, and p-tau181 data. Results CSF AD biomarker measurements with the qualified AlzBio3 immunoassay detects neuropathologic AD hallmarks in preclinical and prodromal disease stages, based on CSF studies in non-ADNI living subjects followed by the autopsy confirmation of AD. Collaboration across ADNI cores generated the temporal ordering model of AD biomarkers varying across individuals because of genetic/environmental factors that increase/decrease resilience to AD pathologies. Discussion Further studies will refine this model and enable the use of biomarkers studied in ADNI clinically and in disease-modifying therapeutic trials.",
keywords = "ADNI, Alzheimer's disease, Aβ, Biomarkers, Cerebrospinal fluid, Disease-modifying therapy, Immunoassay, Mild cognitive impairment, Plasma, Tau",
author = "Kang, {Ju Hee} and Magdalena Korecka and Figurski, {Michal J.} and Toledo, {Jon B.} and Kaj Blennow and Henrik Zetterberg and Teresa Waligorska and Magdalena Brylska and Leona Fields and Nirali Shah and Holly Soares and Dean, {Robert A.} and Hugo Vanderstichele and Petersen, {Ronald C.} and Aisen, {Paul S.} and Saykin, {Andrew J.} and Weiner, {Michael W.} and Trojanowski, {John Q.} and Shaw, {Leslie M.}",
note = "Funding Information: Data collection and sharing for this project was funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904 ) and DOD ADNI ( Department of Defense award number W81XWH-12-2-0012 ). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health ( www.fnih.org ). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Disease Cooperative Study at the University of California, San Diego. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California.This research was also supported by NIH grants AG10124 . J.Q.T. is the William Maul Measy-Truman G. Schnabel Jr. M.D. Professor of Geriatric Medicine and Gerontology. J.-H.K. is supported by grants from the National Research Foundation (NRF) funded by the Korea Government (MSIP) Medical Research Center program (MRC No. 2014009392). Publisher Copyright: {\textcopyright} 2015 Published by Elsevier Inc.",
year = "2015",
month = jul,
day = "1",
doi = "10.1016/j.jalz.2015.05.003",
language = "English (US)",
volume = "11",
pages = "772--791",
journal = "Alzheimer's and Dementia",
issn = "1552-5260",
publisher = "Elsevier",
number = "7",
}